Stock 300158 SHANXI ZHENDONG PHARMACEUTICAL CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

News Shanxi Zhendong Pharmaceutical Co.,Ltd

Equities

300158

CNE100000YR9

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 27/05/2024 am IST 		5-day change 1st Jan Change
4.53 CNY +0.89% Intraday chart for Shanxi Zhendong Pharmaceutical Co.,Ltd -8.11% -32.89%
20/05 Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Board Appointments CI
06/05 Tranche Update on Shanxi Zhendong Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on February 6, 2024. CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Board Appointments
CI
Tranche Update on Shanxi Zhendong Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on February 6, 2024.
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd's Equity Buyback announced on February 6, 2024, has closed with 22,174,904 shares, representing 2.16% for CNY 102.76 million.
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tranche Update on Shanxi Zhendong Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on February 6, 2024.
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd agreed to acquire additional 53.985% stake in Guangdong Longchuangji Pharmaceutical Co., Ltd. from Guangdong Qiangji Pharmaceutical Co., Ltd.
CI
Guangdong Longchuangji Pharmaceutical Co., Ltd. announced that it has received CNY 30 million in funding from Shanxi Zhendong Pharmaceutical Co.,Ltd
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd announces an Equity Buyback for CNY 200 million worth of its shares.
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd authorizes a Buyback Plan.
CI
Guangdong Longchuangji Pharmaceutical Co., Ltd. announced that it expects to receive CNY 30 million in funding from Shanxi Zhendong Pharmaceutical Co.,Ltd
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
CI
FountainVest Capital Partners Fund IV, L.P., a fund managed by Fountain Vest Capital Partners GP4 Ltd. completed the aquistion of Beijing Zhendong Langdi Pharmaceutical Co., Ltd. from Shanxi Zhendong Pharmaceutical Co.,Ltd.
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd(XSEC:300158) added to S&P Global BMI Index
CI
Shanxi Zhendong Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Zhongtai Asset Management Plan No. 45 Single Asset Management Plan, managed by Zhongtai Securities Asset Management Co.,Ltd. completed the acquisition of a 5% stake in Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE : 300158) from Shanxi Zhendong Health Industry Group Co., Ltd.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300158 Stock
  4. News Shanxi Zhendong Pharmaceutical Co.,Ltd